Management of Uncontrolled Hypertension in Aortic Dilation

1. Rationale for Immediate Pharmacologic Intensification

Aortic dilation constitutes target‑organ damage, automatically classifying the patient as high cardiovascular risk and necessitating immediate pharmacologic intensification rather than waiting for lifestyle changes alone. [Hypertension guideline recommendations] 1, 4
Adding an ACE inhibitor or an ARB to the existing bisoprolol regimen is recommended to achieve blood‑pressure control and reduce cardiovascular risk in patients with aortic dilation and hypertension. [Hypertension guideline recommendations] 1, 2, 3

ACE inhibitors or ARBs should be considered first‑line therapy in patients with peripheral arterial disease and aortic disease, including aortic dilation. [European Society of Cardiology (ESC) guidelines] 3
The 2024 ESC guidelines specifically recommend ACE inhibitors or ARBs as the preferred first‑line antihypertensive agents for patients with peripheral arterial and aortic diseases. [ESC] 3

For patients with target‑organ damage such as aortic dilation, the recommended systolic blood‑pressure target is 120–129 mmHg (if tolerated). [ESC] 3
Current readings of 140–160 mmHg are markedly above target and require aggressive management to prevent aortic complications (dissection or rupture). [Circulation guideline summary] 6
Uncontrolled hypertension is a well‑documented risk factor for aortic rupture and dissection, underscoring the critical importance of achieving target pressures. [Circulation] 6

Add a low‑dose ACE inhibitor (e.g., lisinopril 10 mg) or an ARB (e.g., losartan 50 mg) to bisoprolol 5 mg as the preferred first add‑on. [Hypertension guideline recommendations] 1, 2, 4

If blood pressure remains >130/80 mmHg after 4 weeks, titrate the ACE inhibitor/ARB to its full dose (e.g., lisinopril 20–40 mg or losartan 100 mg). [Hypertension] 1, 2

If control is still inadequate, add a thiazide‑like diuretic (e.g., chlorthalidone 12.5–25 mg or indapamide 1.25–2.5 mg). [Hypertension] 1, 2, 4

If three‑drug therapy fails, incorporate spironolactone 25 mg (or, if contraindicated, amiloride, doxazosin, or amlodipine). [Hypertension] 1, 2, 4

Beta‑blockers are not recommended as first‑line monotherapy for hypertension; increasing the beta‑blocker dose without adding complementary agents is suboptimal. [Canadian Cardiovascular Society (CCS) guidelines] 5
Continuing beta‑blocker monotherapy when blood pressure remains uncontrolled delays achievement of target pressure and raises cardiovascular risk. [Hypertension] 1, 5

Combining an ACE inhibitor with an ARB is explicitly discouraged because it increases adverse events without added benefit. [CCS] 5
Non‑dihydropyridine calcium‑channel blockers (diltiazem, verapamil) should not be used together with beta‑blockers due to the risk of excessive bradycardia and heart block. [CCS] 5
Renal function and serum potassium should be checked within 1–2 weeks after initiating an ACE inhibitor/ARB, especially if a diuretic is added later. [CCS] 5

Assess and reinforce medication adherence before escalating therapy, as non‑adherence is a common cause of apparent treatment resistance. [Hypertension] 1, 4

Initiate or optimize high‑intensity statin therapy because aortic dilation with hypertension represents very high cardiovascular risk. [Circulation] 6, 3
Aim for an LDL‑C < 55 mg/dL (< 1.4 mmol/L) with high‑intensity statin therapy. [ESC] 3

Blood‑pressure targets should be reached within 3 months to lower the risk of aortic complications and cardiovascular events. [Hypertension] 1, 2, 4
Refer the patient to a hypertension specialist if blood pressure remains uncontrolled on three‑drug therapy or if secondary hypertension is suspected. [Hypertension] 1, 4